148 related articles for article (PubMed ID: 11916102)
1. Sibutramine in overweight/obese hypertensive patients.
Sharma AM
Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S20-3. PubMed ID: 11916102
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure.
Birkenfeld AL; Schroeder C; Pischon T; Tank J; Luft FC; Sharma AM; Jordan J
Clin Auton Res; 2005 Jun; 15(3):200-6. PubMed ID: 15944869
[TBL] [Abstract][Full Text] [Related]
3. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
6. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Nakou E; Filippatos TD; Liberopoulos EN; Tselepis AD; Kiortsis DN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 Jul; 9(10):1629-39. PubMed ID: 18570597
[TBL] [Abstract][Full Text] [Related]
7. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.
Faria AN; Ribeiro Filho FF; Lerario DD; Kohlmann N; Ferreira SR; Zanella MT
Arq Bras Cardiol; 2002 Feb; 78(2):172-80. PubMed ID: 11887193
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
9. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
[TBL] [Abstract][Full Text] [Related]
10. Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
Gürsoy A; Erdoğan MF; Cin MO; Cesur M; Başkal N
Endocr Pract; 2005; 11(5):308-12. PubMed ID: 16191490
[TBL] [Abstract][Full Text] [Related]
11. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
Gaciong Z; Placha G
J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
[TBL] [Abstract][Full Text] [Related]
13. Sibutramine and the sympathetic nervous system in obese humans.
Haynes WG; Egri Z
Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
[No Abstract] [Full Text] [Related]
14. Sibutramine. A review of its contribution to the management of obesity.
McNeely W; Goa KL
Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
[TBL] [Abstract][Full Text] [Related]
15. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
[TBL] [Abstract][Full Text] [Related]
16. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Seimon RV; Espinoza D; Ivers L; Gebski V; Finer N; Legler UF; Sharma AM; James WP; Coutinho W; Caterson ID
Int J Obes (Lond); 2014 Sep; 38(9):1165-71. PubMed ID: 24406481
[TBL] [Abstract][Full Text] [Related]
17. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
19. The importance of obesity in diabetes and its treatment with sibutramine.
Van Gaal LF; Peiffer FW
Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S24-8. PubMed ID: 11916103
[TBL] [Abstract][Full Text] [Related]
20. The role of sibutramine in weight management--towards a blueprint for a sibutramine weight management system.
James WP; Finer N
Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S34-8. PubMed ID: 11916105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
